Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257222 | 0.76 | USP2 (0.53) | USP2KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL7477443 | 0.76 | KDM4E (0.61) | USP2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL16416948 | 0.73 | USP2 (0.71) | USP2KMT2AKDM4EALDH1A1TSHR | |
| SCHEMBL20519235 | 0.72 | USP2 (0.49) | USP2KMT2AGPR35L3MBTL1HTT | |
| SCHEMBL22870151 | 0.72 | KDM4E (0.47) | USP2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL15197088 | 0.71 | KMT2A (0.44) | USP2KMT2AALDH1A1LMNATSHR | |
| SCHEMBL23264663 | 0.69 | USP2 (0.46) | USP2KMT2AGPR35GRIA2GRIA4 | |
| SCHEMBL28895524 | 0.69 | USP2 (0.54) | USP2KMT2AGPR35TSHRHPGD | |
| SCHEMBL70763 | 0.69 | KDM4E (0.46) | USP2KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL19332132 | 0.69 | USP2 (0.49) | USP2KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423116-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7256257-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060229253-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. | 2006-10-12 | — | — | US | disclosed |
| US-7098308-B2 | Pentapetide containing a proline amino acid; cytotoxic agent | SEATTLE GENETICS, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1390393-A4 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. | 2005-05-26 | — | — | US | disclosed |
| US-6884869-B2 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20050009751-A1 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | SEAGEN INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1390393-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | Seattle Genetics, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| WO-2002088172-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113308-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | USP2 3420/4885KMT2A 4319/4885KDM4E 3840/4885 |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | NGLY1, VIP, DNPEP | USP2 2833/4885KMT2A 4624/4885KDM4E 4594/4885 |
| US-20050009751-A1 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | VIP, NGLY1, DNPEP | USP2 3420/4885KMT2A 4319/4885KDM4E 3840/4885 |
| US-20060229253-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | USP2 3080/4885KMT2A 4617/4885KDM4E 4483/4885 |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | USP2 3420/4885KMT2A 4319/4885KDM4E 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.